More recently, semaglutide, a glucagon-like peptide-1 receptor agonist (GLP1-RA), and tirzepatide, a dual GLP1 and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist, have been shown to improve health status and body weight in patients with HFpEF and obesity [8,9]. Here, GLP1R is linked to obesity disorder.